The Biologics Testing Global Market Report 2023, provides comprehensive information on the biologics testing market across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.
Learn More On The Biologics Testing Market’s Growth:
https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report
As per The Business Research Company’s Biologics Testing Global Market Report 2023, the market size is expected to grow from $4.42 billion in 2022 to $5.09 billion in 2023 at a compound annual growth rate (CAGR) of 15.13%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global biologics testing market size is expected to reach $9.24 billion in 2027 at a CAGR of 16.09%.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=10276&type=smp
Product Innovations are a key trend gaining popularity in the biologics testing market. Companies operating in the biologics testing market are adopting new innovative products to sustain their position in the market. For instance, in December 2022, Charles River Laboratories International, Inc., a US-based non-clinical contract research organization, launched the Endosafe® Nexus 200TM, a new addition to its broad endotoxin testing line. The Nexus 200 is a data integrity compliant, fully robotic instrument that is the next step in Charles River's evolution. It uses Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology and can process simple or complex serial dilutions for water, in-process, and final product testing. The system, which is run on Endosafe EndoScan-V version 6.1, enables data to be exported into a Laboratory Information Management System (LIMS) interface and offers enhanced traceability, security, and data management on an integrated touch screen.
The biologics testing market is segmented:
1) By Product: Reagents And Kits, Instruments, Other Products
2) By Test Type: Endotoxin Test, Sterility Test, Mycoplasma Tests, Bioburden Tests, Residual Host-Cell Proteins And DNA Detection Tests, Virus Safety Test, Other Test Types
3) By Application: Vaccine Development And Manufacturing, Monoclonal Antibodies Development And Manufacturing, Cellular And Gene Therapy Products Development And Manufacturing, Blood And Blood Products Development And Manufacturing, Other Applications
North America was the largest region in the biologics testing market in 2022.
The table of contents in TBRC’s biologics testing market report includes:
1. Executive Summary
2. Biologics Testing Market Characteristics
3. Biologics Testing Market Trends And Strategies
4. Biologics Testing Market - Macro Economic Scenario
5. Biologics Testing Market Size And Growth
......................
26. Africa Biologics Testing Market
27. Biologics Testing Market Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Biologics Testing Market
29. Biologics Testing Market Future Outlook and Potential Analysis
30. Appendix
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Biologics are pharmaceutical products that are extracted from biological sources.
It is a mandatory process in these companies for the quality control of raw materials as well as for process control and validation of end products.Major Growth Drivers:The major factors driving the growth of this market are the growth in pharmaceutical & biotechnology industry driven by government support, the positive trend of R investment in the life science sector, increasing number of drug launches, and high incidence & large economic burden of chronic diseases.
In the coming years, emerging markets and increasing pharmaceutical outsourcing are expected to offer growth opportunities for players in the biologics safety testing market.Expected Revenue Growth:The global biologics safety testing market is expected to reach USD 4.90 Billion by 2022 from USD 2.75 Billion in 2017, at a CAGR of 12.2% during forecast period.Accessories to Fuel the Growth of Biologics Safety Testing Market :Pharmaceutical and biotechnology companies are the largest end users in the biologics safety testing market.
Biologics safety testing is carried out at all levels of manufacturing to minimize the risk of product contamination in these industries.
According to the International Trade Administration, the global pharmaceuticals market is projected to grow from USD 1 trillion in 2015 to USD 1.3 trillion by 2020, at a CAGR of 4.9%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144By product, kits & reagents segment is expected to grow at the highest growth rate during the forecast periodThe kits & reagents segment is projected to register the highest during the forecast period.
The growth of this market segment is driven by repeat purchase of kits and reagents as compared to instruments and increasing adoption of kit-based testing.By application, Vaccine and Therapeutics Development segment to record the highest CAGR during the forecast periodVaccine and Therapeutics Development segment is projected to register a higher CAGR during the forecast period.
According to the new market research report “Biologics Safety Testing Market by Product & Service (Consumables, Instrument, Services), Application (Vaccine, Monoclonal Antibodies, Blood products, Cell & Gene Therapy Products), Test Type (Endotoxin, Myoplasm, Sterility Test) – Global Forecast to 2026″, published by MarketsandMarkets™, the global market is projected to reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period.Browse in-depth TOC on “Biologics Safety Testing Market”142 – Tables42 – Figures185 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144Covid-19 Impact On The Global Biologics Saftey Testing MarketCOVID-19 is an infectious disease caused by the most recently discovered novel coronavirus.
Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic.
The World Health Organization (WHO) officially declared the outbreak of COVID-19 a pandemic.
A mix of established pharmaceutical and biopharmaceutical companies, along with the players of the Biologics safety testing market, have stepped forward to contribute to worldwide research efforts by providing biologics safety testing for developing safety test kits and testing for treatments and vaccines manufacturing that target the infection caused by the novel Coronavirus.The growth of the global biologics safety market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination, and rising biopharmaceuticals R activities and investments.The residual host-cell proteins and DNA detection tests segment accounted for the largest share of the Biologics Safety Testing market in 2020.Based on test type, the market is segmented into residual host-cell proteins and DNA detection tests, endotoxin tests, sterility tests, mycoplasma tests, bioburden tests, and virus safety tests.
In 2020, the residual host-cell proteins and DNA detection tests segment accounted for the largest market share.
The rising demand for residual HCP and DNA detection tests for recombinant proteins and increasing focus on the quality of drugs are the major factors driving the growth of this segment.The monoclonal antibodies manufacturing segment accounted for the largest market share of the market in 2020.Based on application, the biologics safety testing market is segmented into monoclonal antibodies manufacturing, vaccines manufacturing, blood and blood products manufacturing, cellular and gene therapy products manufacturing, and other applications.
